12月2日 - ** 药物开发商Jasper Therapeutics JSPR.O的股价在盘前交易中上涨17%至2.02美元
** 该公司称其实验性药物briquilimab的早期研究改善了过敏性哮喘患者的肺功能并减少了气道炎症
** 早期研究在加拿大招募了约17名患者；药物耐受性良好，没有严重的安全性问题 - JSPR
** 公司的briquilimab靶向肥大细胞，肥大细胞会引发哮喘症状和过敏反应 - JSPR
** 截至上次收盘，该公司股票今年累计下跌约 92
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.